ClinicalTrials.gg
Active, not recruitingNCT04297995Updated Aug 8, 2023

Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors

A Phase 2 interventional study of HLX10 and HLX07 in Head and Neck Squamous Cell Carcinoma, sponsored by Shanghai Henlius Biotech. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-08-08.

Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2024, 2 years 5 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
131
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 290 studies in Squamous Cell Carcinoma of Head and Neck with a site in China — 171 open to participants now, 205 under way, 25 of them phase 3. Squamous Cell Carcinoma of Head and Neck · China.

Planned enrollment
79th of 265
131 · median 68
Started
2020
with 17 others
Phase 2
139 of 290
86 open now
Primary completion
2024-05
later than 13 of 204 live
Registered
38th of 290
by date

Among the 290 studies in Squamous Cell Carcinoma of Head and Neck with a site in China, this one is the 79th largest by planned enrollment of the 265 interventional ones that give a count, is one of 18 that started in 2020, is one of 139 in phase 2, reaches primary completion later than 13 of the 204 other live ones, and was the 38th registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

171 of the 290 studies in Squamous Cell Carcinoma of Head and Neck with a site in China are open now. Recruiting first, the newest first:

166 more — sign in →

All 171 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 290 studies in Squamous Cell Carcinoma of Head and Neck with a site in China, or all of them as a file.
02

Study summary

Part1:

A mutilpe-center, open-label, Phase II clinical trial to evaluate the efficacy and the safety of HLX10 in combination with HLX07 in patients with advanced advanced head and neck tumors.

Part2:

A randomized, double-blind, multi-center, phase II clinical study to evaluate the clinical efficacy and safety of HLX10 in combination with HLX07 and chemotherapy versus HLX10 in combination with placebo and chemotherapy in the first-line treatment of R/M HNSCC.

Read the detailed description

Part 1:

This is an open label study. Sample size recommendations for this phase II study are determined according to Simon's two-stage Optimal design.

In the first stage, 13 patients will be accrued. The patients will receive 3 mg/kg of HLX10 every two weeks infusion combined with 600 mg HLX07 weekly (stage 1L). These patients will be assessed for treatment response after 8 weeks of first infusion of study drugs. If there are 3 or fewer responsive patients in these 13 patients, additional 13 patients will be accrued. These additional 13 patients will receive 3 mg/kg of HLX10 every two weeks infusion combined with 800 mg HLX07 weekly (Stage 1H). If 3 or fewer responses after eight weeks treatment noted in these 13 patients in stage 1H, the trial will be stopped.

If 4 or more patients are responsive to therapy in stage 1, the trial will be continued to stage 2, 30 additional patients will be accrued to reach a total of 43 patients. These additional 30 patients will receive the same dose of regimen as the prior patients.

Part 2:

This is a randomized, double-blind, multi-center, phase II clinical study to evaluate the clinical efficacy and safety of HLX10 in combination with HLX07 and chemotherapy versus HLX10 in combination with placebo and chemotherapy in the first-line treatment of R/M HNSCC. Approximately 75 first-line R/M HNSCC subjects are planned to be recruited. The sample size calculation is not based on the statistical hypothesis.

Eligible subjects after screening will be randomly assigned to the treatment group (group A) or the control group (group B) in a ratio of 2:1, with PD-L1 CPS (≥ 20 and \< 20) as the stratification factor at randomization (Figure 1):

Group A: approximately 50 subjects, HLX10 in combination with HLX07 and chemotherapy (cisplatin in combination with 5-FU).

Group B: approximately 25 subjects, HLX10 in combination with placebo and chemotherapy (cisplatin in combination with 5-FU).

Cisplatin may be replaced with carboplatin when the subject is judged intolerant to cisplatin by the INV.

The study will be unblinded overall for ORR analysis approximately 3 months after the first dose of the last subject.

03

Conditions studied

  • Head and Neck Squamous Cell Carcinoma
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Part1

Inclusion Criteria:

  1. Eligible patients must be 18 years of age or older or per local regulation AND younger than 80 years old age.
  2. Patients with -proven recurrent (not amenable to locally curative treatment options) or , squamous cell carcinoma of the head and neck with previously failed platinum-based chemotherapy and expression (combined positive score ≥ 1) as determined by immunohistochemistry (IHC) stain. (Patient must be able to provide tissue for PD-L1 biomarker analysis from a core or excisional ; fine needle aspirate is not sufficient.: A newly obtained biopsy; within 90 days prior to start of study treatment; is preferred but an archival sample is acceptable.)
  3. Lesion must be measurable based on , version 1.1.
  4. (ECOG) performance status of ≤ 1 at the time of study entry.
  5. Able to provide .
  6. A longer than three months.
  7. Adequate hematologic functions, as defined by: (ANC) ≥ 1500/mm3; a (Hb) level ≥ 9 gm/dL; a count ≥ 100,000/mm3.
  8. Adequate hepatic function defined by: a total level ≤ 1.5x of (ULN); (AST) and alanine transaminase (ALT) levels ≤ 2.5 x of ULN or ≤ 5x of ULN in known hepatic metastases.
  9. Adequate renal function, as defined by the rate ≥ 50 mL/minute calculated using Cockcroft-Gault formula. In patient with extreme body weight ( [BMI] \< 18.5 or > 30), estimated (GFR) ≥ 50mL/min calculated using Modification of Diet in Renal Disease (MDRD) formula is acceptable.
  10. Adequate cardiac function defined as (LVEF) ≥ 50% measured by multigated acquisition (MUGA) scan or cardiac ultrasound.
  11. Use of effective measures if procreative potential exists .
  12. At least 28 days from prior major surgery, prior cytotoxic chemotherapy, or prior therapy with agents (or medical device) and curative radiotherapy or palliative radiotherapy to target lesion before the first infusion of investigational product.
  13. Able to follow the procedures as required by the study protocol and must agree to provide tumor tissue for programmed cell death 1 (PD-L1) expression analyses, EGFR mutation status, and biomarker assessment.

Exclusion Criteria:

  1. Patients who still have persistent ≥ grade 2 toxicities from prior therapies.
  2. Patients with primary nasopharynx cancers.
  3. Squamous cell carcinoma of unknown primary in cervical lymph node.
  4. Concurrent unstable or uncontrolled medical conditions. Either of the followings:

    • Active systemic infections currently under treatment with antimicrobial agents;
    • Poorly controlled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥100 mmHg), or poor compliance with anti-hypertensive agents;
    • arrhythmia, unstable angina pectoris, congestive heart failure (class III or IV of [NYHA]) or acute myocardial infarction within 12 months;
    • Uncontrolled diabetes or poor compliance with hypoglycemic agents;
    • The presence of chronically unhealed wound or ulcers;
    • Other chronic diseases, which, in the opinion of the investigator, could compromise safety of the patient or the integrity of study.
  5. Newly-diagnosed or symptomatic (patients with a history of brain metastases must have received definitive surgery or radiotherapy, must be clinically stable, and must not taking for brain edema for at least 14 days to be allowed in the study). Anticonvulsants are allowed.
  6. Any concurrent other than basal cell carcinoma or carcinoma in situ of the cervix. (Patients with a previous malignancy but without evidence of disease for ≥ 3 years can participate).
  7. Pregnancy (confirmed by serum beta human chorionic gonadotropin [ßHCG]) or breast-feeding.
  8. Known history of infection (HIV).
  9. Patient who has an active or a documented history of disease.
  10. Patient who has active (HBV DNA titer > 100 IU/mL or > 500 copies/mL) or (defined as anti-HCV antibody reactive and/ or detectable HCV RNA > 15 IU/L).
  11. Patient who has a history of interstitial lung disease.
  12. Have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of autoimmune disease.
  13. Patients who have failed systemic anti-EGFR monoclonal antibody therapies (who have PD or PFS less than 3 months during anti EGFR treatment) or have been received more than 3 regimens.
  14. Patients who previously have severe allergic reaction to anti-EGFR monoclonal antibody ( grade ≥3).
  15. Patients who have previously received immune check point therapy, including but not limit to anti-PD1 and anti-PDL1.
  16. The patient is the investigator, sub-investigator or any one directly involved in the conduct of the study.
  17. Patient has a history or current evidence of any condition or disease that could confound the results of the study, or study or is not the best interest of the patient to participate, in the opinion of Investigator.

Part2

Inclusion Criteria:

  1. Histologically or cytologically confirmed R/M HNSCC that is considered incurable by local therapies.
  2. Have not received any systemic anti-tumor therapy for R/M HNSCC. Patients who have received systemic anti-tumor therapy (including anti-EGFR antibody drugs) as part of comprehensive treatment at the locally advanced stage are allowed to be enrolled if the systemic therapy has been completed for at least 6 months before signing the informed consent form (ICF).

    • Tumor types to be included: primary cancers of the oropharynx, oral cavity, hypopharynx, and larynx.
    • Patients with primary nasopharyngeal cancer are not allowed to be enrolled.
    • Willing and able to provide the written ICF to participate in this study.
  3. Age ≥ 18 years at the time of signing the ICF.
  4. Have as assessed by the INV per RECIST v1.1. Previously irradiated lesions may be considered measurable if progression has been confirmed in such lesions.
  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at the time of enrollment.
  6. Normal major organ functions.
  7. Able to provide tissue samples from needle biopsy or excisional biopsy (fine-needle aspiration is unacceptable) for determination of EGFR and PD-L1 expression. Patients with oropharyngeal cancer are required to provide additional tissue samples for HPV (P16) status testing. Tissue samples should be re-collected if the quantity is not adequate.
  8. Female subjects with must be tested negative for serum pregnancy test within 7 days prior to the first dose.
  9. Female subjects with childbearing potential should agree to use two methods of contraception, undergo sterilization, or avoid heterosexual sex during the treatment and until 180 days after the last dose. Subjects with childbearing potential refer to those who have not undergone sterilization or have stopped menstruating for less than 1 year. Subjects are allowed to choose abstinence as a contraceptive measure if abstinence is their normal lifestyle.
  10. Male subjects should agree to take adequate contraceptive measures from the first dose until 180 days after the last dose. Subjects are allowed to choose abstinence as a contraceptive measure if abstinence is their normal lifestyle.

Exclusion Criteria:

  1. Subjects who are candidates for radical locoregional therapy.
  2. PD within 6 months after completion of radical systemic therapy (including anti-EGFR antibody drugs) for locally advanced HNSCC.
  3. Have received radiotherapy (or other non-systemic therapies) within 2 weeks prior to the first dose or still have AEs related to previous treatment that have not fully recovered (e.g., to ≤ grade 1 or to baseline).

    • Subjects with ≤ grade 2 neuropathy, or ≤ grade 2 alopecia, or laboratory parameters meeting Article 6 of the inclusion criteria are not subject to this exclusion criterion and are allowed to be enrolled.
    • For subjects who have undergone major surgery, surgery-related toxicity or complications must be fully recovered before the first dose. The major surgery in this study is defined as a surgery requiring at least 3 weeks of recovery for a subject to be able to receive the treatment in this study.
  4. Currently on other clinical study treatment, or have received treatment with other IPs or medical devices within 4 weeks prior to the first dose. Subjects who are in the follow-up period of the previous clinical study (not in the study treatment period) are allowed to be enrolled.
  5. Life expectancy of less than 3 months and/or rapid disease progression (e.g., tumor bleeding, uncontrolled neoplastic pain) as judged by the INV.
  6. Myocardial infarction or poorly controlled arrhythmia (including ≥ 450 ms for males and ≥ 470 ms for females) (QTc intervals are calculated by Fridericia's formula) within 6 months prior to the first dose.
  7. Class III to IV cardiac insufficiency according to New York Heart Association (NYHA) classification or a left ventricular ejection fraction (LVEF) \< 50% by cardiac color Doppler.
  8. Subjects with inadequately controlled hypertension (systolic blood pressure ≥ 150 mmHg and/or diastolic blood pressure ≥ 100 mmHg), showing a history of hypertensive crisis or hypertensive encephalopathy.
  9. Artery/vein thrombosis or thromboembolism events, including pulmonary embolism, occurred within 6 months prior to the first dose.
  10. Subjects who have a diagnosis of immunodeficiency or are receiving systemic steroid treatment or any other forms of immunosuppressive therapy within 7 days prior to the first dose. Corticosteroids can be used as prophylactic medications for anaphylaxis (e.g., intravenous contrast agent) or for prophylactic management of chemotherapy-related AEs as specified in the protocol. Corticosteroids at physiologic doses are allowed upon consultation with the sponsor.
  11. Other malignancies diagnosed and/or treated within 3 years prior to the first dose with the exception of: curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, radically resected cervical carcinoma in situ, and radically resected breast cancer in situ. Other exceptions may be considered in consultation with the sponsor.
  12. Known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Note: Subjects with previously treated brain metastases may participate in this study when meeting the following criteria: stable condition for at least 4 weeks prior to the first dose (showing no imaging evidence of progression (under the same imaging mode for each evaluation, either MRI or CT scan), with all neurological symptoms back to baseline); no evidence of new or expanded brain metastases; no use of steroids within at least 7 days prior to the first dose. Carcinomatous meningitis should be excluded regardless of clinical stability.
  13. Active autoimmune disease requiring systemic therapy (e.g., disease-modifying drugs, corticosteroids, or immunosuppressants) present within 2 years prior to the first dose. Alternative therapies (e.g., thyroxine, insulin, or physiologic corticosteroids for adrenal or pituitary insufficiency) are not considered systemic therapies.
  14. Have received transplantation of allogeneic tissues or parenchymal organs.
  15. A history of previous or current pneumonitis (non-infectious) requiring steroid therapy.
  16. Active infection requiring systemic therapy.
  17. Subjects whose medical history or current abnormal laboratory data may cause confusion about study results or interference in their full participation in this study, or for whom participation in this study is not in their best interest as assessed by the INV.
  18. Known mental disorders or drug abuse that will interfere with the subject's compliance with the requirements of this study.
  19. Pregnant or lactating women, or those who prepare to become pregnant or give birth during the expected duration of this study (from the screening visit to 180 days after the last dose).
  20. Patients who have been treated with immune checkpoint inhibitors (including but not limited to anti-PD-1 or anti-PD-L1 antibody drugs).
  21. Known history of human immunodeficiency virus (HIV) infection.
  22. Positive (+) for hepatitis B surface antigen (HBsAg) or positive (+) for hepatitis B core antibody (HBcAb), and with hepatitis B virus deoxyribonucleic acid (HBV-DNA) ≥ 2500 copies/mL or 500 IU/mL, or presence of active hepatitis determined clinically (patients whose HBV-DNA has decreased below the above criteria after antiviral therapy and who are willing to receive antiviral therapy throughout the study are allowed to be enrolled); patients with hepatitis C (positive for HCV-RNA).
  23. Have received within 30 days prior to the first dose.
Terms in these criteria, in plain language(36)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
131 participants (estimated)

Study arms

  • Experimental
    Part 1: HLX10 Plus HLX07 (stage 1L)

    3 mg/kg of HLX10 every two weeks infusion combined with 600 mg HLX07 weekly

    Drug: HLX10 · Drug: HLX07

  • Experimental
    Part 1: HLX10 Plus HLX07 (Stage 1H)

    3 mg/kg of HLX10 every two weeks infusion combined with 800 mg HLX07 weekly

    Drug: HLX10 · Drug: HLX07

  • Experimental
    Part 2: HLX10 Plus HLX07 Plus Chemotherapy

    HLX10 (300 mg) Plus HLX07 (1000 mg) Plus Cisplatin (100 mg/m2) Plus 5-FU (1000 mg/m2/day, 1-4 days). Cisplatin will be switched to carboplatin in case of intolerance to cisplatin. Up to 6 cycles of chemotherapy.

    Drug: HLX10 · Drug: HLX07 · Drug: Cisplatin/Carboplatin · Drug: 5-FU

  • Placebo comparator
    Part 2: HLX10 Plus HLX07 Placebo Plus Chemotherapy

    HLX10 (300 mg) Plus HLX07 Placebo (1000 mg) Plus Cisplatin (100 mg/m2) Plus 5-FU (1000 mg/m2/day, 1-4 days). Cisplatin will be switched to carboplatin in case of intolerance to cisplatin. Up to 6 cycles of chemotherapy.

    Drug: HLX10 · Drug: HLX07 placebo · Drug: Cisplatin/Carboplatin · Drug: 5-FU

Interventions

  • DrugHLX10

    Part 1: HLX10 3 mg/kg biweekly. Part 2: HLX10 300 mg every three weeks.

  • DrugHLX07

    Part 1: HLX07 600 mg weekly (stage 1L). Part 1: HLX07 800 mg weekly (stage 1H). Part 2: HLX07 1000 mg every three weeks.

  • DrugHLX07 placebo

    HLX07 placebo 1000 mg every three weeks

  • DrugCisplatin/Carboplatin

    Drug pages: Cisplatin · Carboplatin

    Cisplatin 100 mg/m2 every three weeks. Cisplatin will be switched to carboplatin in case of intolerance to cisplatin. Up to 6 cycles.

  • Drug5-FU

    5-FU 1000 mg/m2/day, 1-4 days, every three weeks. Up to 6 cycles.

06

What researchers measure

Primary outcomes

  1. Part1: Efficacy-ORR

    Objective Response Rate (ORR)

    Time frame: at 16 weeks after first dose

  2. Part1: Safety-adverse event profile

    The proportion of patients suffered from drug related toxicities.

    Time frame: up to one year

  3. Part2: Efficacy-ORR (IRRC)

    Objective Response Rate (ORR) assessed by the Independent Radiological Review Committee (IRRC) per RECIST v1.1.

    Time frame: at 3 months after first dose

Secondary outcomes

  1. Efficacy-Best ORR

    Best response rate (Best ORR)

    Time frame: up to one year

  2. Efficacy-PFS

    Progression-free survival (PFS)

    Time frame: up to one year

  3. Efficacy-OS

    Overall survival (OS)

    Time frame: up to one year

  4. The number of presence patients that develop of anti-durg antibody (immunogenicity).

    Time frame: up to one year

  5. maximum concentration (Cmax)

    Time frame: up to one year

  6. trough concentration (Ctrough)

    Time frame: up to one year

  7. half-life (T1/2)

    Time frame: up to one year

  8. clearance rate (CL)

    Time frame: up to one year

  9. volume of distribution (Vss)

    Time frame: up to one year

  10. area under concentration (AUC0-tau)

    Time frame: up to one year

07

Study locations

1 site
  • Shanghai Henlius Biotech Inc.
    Shanghai, Shanghai 200233, China
08

References and documents

Publications

  • Y. Guo, W. Wang, G. Cao, et al. A phase 2 study of serplulimab plus HLX07 in patients with advanced head and neck tumours. Abstract Book. ICHNO-ECHNO 2022: 590

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2020 (actual). Primary completion is estimated for May 2024, 46 months after the start.

Of 68 industry-sponsored phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 60. This study's planned 46 months is close to that.

Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2020
First posted
Mar 6, 2020
StartActual
Jul 29, 2020
Primary completionEst.
May 30, 2024
CompletionEst.
Jun 30, 2025
Last update
Aug 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04297995
Responsible party
Sponsor
First posted
Mar 6, 2020
Start date
Jul 29, 2020
Primary completion
May 30, 2024 (estimated)
Completion
Jun 30, 2025 (estimated)
Last update
Aug 8, 2023

Study contacts

Ye Guo, PhD
principal investigator · Shanghai East Hospital
Guochun Cao
principal investigator · Jiangsu Cancer Institute & Hospital
Meiyu Fang
principal investigator · Cancer Hospital of The University of Chinese Academy of Sciences
Guangyuan Hu
principal investigator · Tongji Hospital
Xiaohui He
principal investigator · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Yan Sun
principal investigator · Peking University Cancer Hospital & Institute
Wei Wang
principal investigator · Hunan Cancer Hospital
Shubin Wang
principal investigator · Peking University Shenzhen Hospital
Qingyuan Zhang
principal investigator · The Second Affiliated Hospital of Harbin Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HLX07

Start the discussion